Pharmaceutical composition for inducing aging

JP2026094392APending Publication Date: 2026-06-09TOKYO METROPOLITAN GERIATRIC HOSPITAL & INST OF GERONTOLOGY
View PDF 1 Cites 0 Cited by

Patent Information

Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
TOKYO METROPOLITAN GERIATRIC HOSPITAL & INST OF GERONTOLOGY
Filing Date
2026-03-09
Publication Date
2026-06-09

AI Technical Summary

Benefits of technology

【0006】 本発明の医薬組成物によれば、効果的に線維芽細胞増殖因子受容体4(FGFR4)を発現する細胞に老化を誘導することができる。

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2026094392000006
    Figure 2026094392000006
  • Figure 2026094392000007
    Figure 2026094392000007
  • Figure 2026094392000008
    Figure 2026094392000008
Patent Text Reader

Abstract

The object of the present invention is to provide an effective therapeutic pharmaceutical composition for pancreatic cancer. [Solution] The above problem can be solved by a pharmaceutical composition containing the fibroblast growth factor receptor 4 inhibitor and senescent cell death inducer of the present invention as active ingredients.
Need to check novelty before this filing date? Find Prior Art

Claims

1. A pharmaceutical composition for inducing senescence in cells expressing fibroblast growth factor receptor 4 (FGFR4), comprising BLU9931, BLU-554, or lovritinib as an active ingredient.

2. A pharmaceutical composition for inducing aging according to claim 1, and a pharmaceutical composition for treating pancreatic cancer comprising quercetin.

3. A method for inducing senescence in cells expressing fibroblast growth factor receptor 4 (FGFR4), comprising contacting FGFR4-expressing cells with an effective amount of BLU9931, BLU-554, or lovritinib.

4. A pharmaceutical composition for the treatment of pancreatic cancer, comprising quercetin as an active ingredient, which is used in combination with the anti-aging pharmaceutical composition described in claim 1, and is intended for patients receiving treatment with the anti-aging pharmaceutical composition described in claim 1.